CN109982686A - 普利多匹定用于治疗rett综合征的用途 - Google Patents

普利多匹定用于治疗rett综合征的用途 Download PDF

Info

Publication number
CN109982686A
CN109982686A CN201780071045.XA CN201780071045A CN109982686A CN 109982686 A CN109982686 A CN 109982686A CN 201780071045 A CN201780071045 A CN 201780071045A CN 109982686 A CN109982686 A CN 109982686A
Authority
CN
China
Prior art keywords
day
pridopidine
subject
puli
symptom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780071045.XA
Other languages
English (en)
Chinese (zh)
Inventor
米甲·杰瓦
拉尔夫·劳弗
迈克尔·海登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prinia Medical Development Co Ltd
Original Assignee
Prinia Medical Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prinia Medical Development Co Ltd filed Critical Prinia Medical Development Co Ltd
Publication of CN109982686A publication Critical patent/CN109982686A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
CN201780071045.XA 2016-09-16 2017-09-15 普利多匹定用于治疗rett综合征的用途 Pending CN109982686A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16
US62/395,854 2016-09-16
PCT/US2017/051803 WO2018053280A1 (en) 2016-09-16 2017-09-15 Use of pridopidine for treating rett syndrome

Publications (1)

Publication Number Publication Date
CN109982686A true CN109982686A (zh) 2019-07-05

Family

ID=61619744

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780071045.XA Pending CN109982686A (zh) 2016-09-16 2017-09-15 普利多匹定用于治疗rett综合征的用途

Country Status (13)

Country Link
EP (2) EP3512506B1 (https=)
JP (1) JP6977029B2 (https=)
CN (1) CN109982686A (https=)
AU (1) AU2017326013B2 (https=)
BR (1) BR112019005040A2 (https=)
CA (1) CA3036984C (https=)
DK (2) DK3512506T3 (https=)
ES (2) ES2909557T3 (https=)
HU (1) HUE058314T2 (https=)
IL (1) IL265342B2 (https=)
MX (1) MX388845B (https=)
PL (2) PL4005570T3 (https=)
WO (1) WO2018053280A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744923A (zh) * 2020-11-19 2023-09-12 普瑞尼亚神经治疗有限公司 普利多匹定及类似物用于治疗rett综合征的用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
WO2018039475A1 (en) 2016-08-24 2018-03-01 Teva Pharmaceuticals International Gmbh Use of pridopidine for treating dystonias
ES3025836T3 (en) 2016-08-24 2025-06-09 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating functional decline
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
EP3920924A4 (en) 2019-02-04 2022-11-16 Prilenia Neurotherapeutics Ltd. LOW-DOSE PRIDOIDIN FOR THE TREATMENT OF PARKINSON'S DISEASE AND OTHER PARKINSONIC-RELATED DISEASES

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1420869A (zh) * 1999-12-22 2003-05-28 A·卡尔松研究股份公司 新的多巴胺神经传递调节剂
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
WO2015112601A1 (en) * 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2016138130A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SG188298A1 (en) 2010-09-03 2013-04-30 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
HK1206297A1 (en) 2012-04-04 2016-01-08 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1420869A (zh) * 1999-12-22 2003-05-28 A·卡尔松研究股份公司 新的多巴胺神经传递调节剂
WO2013086425A1 (en) * 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
WO2015112601A1 (en) * 2014-01-22 2015-07-30 IVAX International GmbH Modified release formulations of pridopidine
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
WO2016138130A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Use of pridopidine to improve cognitive function and for treating alzheimer's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
严世贵等: "《临床小儿骨科学》", 30 April 2010, 中国医药科技出版社 *
王华主编: "《儿科神经综合症》", 30 April 2014, 辽宁科学技术出版社 *
邬玲仟等主编: "《中华民族基因组多态现象研究 人类单基因遗传疾病》", 30 November 2015, 西安交通大学出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116744923A (zh) * 2020-11-19 2023-09-12 普瑞尼亚神经治疗有限公司 普利多匹定及类似物用于治疗rett综合征的用途
CN116744923B (zh) * 2020-11-19 2026-03-13 普瑞尼亚神经治疗有限公司 普利多匹定及类似物用于治疗rett综合征的用途

Also Published As

Publication number Publication date
PL3512506T3 (pl) 2022-05-30
IL265342A (en) 2019-05-30
JP2019532926A (ja) 2019-11-14
EP4005570B1 (en) 2024-05-15
MX388845B (es) 2025-03-20
HUE058314T2 (hu) 2022-07-28
JP6977029B2 (ja) 2021-12-08
AU2017326013A1 (en) 2019-04-11
EP3512506A4 (en) 2020-05-27
ES2909557T3 (es) 2022-05-09
DK4005570T3 (da) 2024-08-19
PL4005570T3 (pl) 2024-09-23
BR112019005040A2 (pt) 2019-07-16
AU2017326013B2 (en) 2020-12-24
EP3512506B1 (en) 2022-01-26
CA3036984C (en) 2023-07-18
WO2018053280A1 (en) 2018-03-22
DK3512506T3 (da) 2022-04-19
ES2986807T3 (es) 2024-11-12
IL265342B2 (en) 2023-06-01
EP4005570A1 (en) 2022-06-01
EP3512506A1 (en) 2019-07-24
CA3036984A1 (en) 2018-03-22
MX2019003069A (es) 2019-09-02

Similar Documents

Publication Publication Date Title
CN109982686A (zh) 普利多匹定用于治疗rett综合征的用途
Minshawi et al. Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach
Lotfipour et al. Targeted deletion of the mouse α2 nicotinic acetylcholine receptor subunit gene (Chrna2) potentiates nicotine-modulated behaviors
US20200276136A1 (en) Method of treating selected patient population experiencing dravet syndrome
US11752111B2 (en) Use of cannabidivarin in the treatment of autism spectrum disorder, associated disorders and schizophrenia
KR20160037169A (ko) 레트 증후군 및 그를 위한 치료
Liu et al. A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1
US20240398778A1 (en) Use of pridopidine for treating rett syndrome
McCarthy et al. Behavioral, neurotransmitter and transcriptomic analyses in male and female Fmr1 KO mice
Clemensen et al. Transdermal fentanyl solution provides long-term analgesia in the hind-paw incisional model of postoperative pain in male rats
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
Grizzard et al. Unbiased genetics identifies a glutamatergic signaling network as a mediator of daily sleep patterns
Patil et al. A BRIEF INTRODUCTION ON ASTHMA.
HK40009961B (en) Use of pridopidine for treating rett syndrome
US20220119819A1 (en) Formulation
Suess Cocaine Intake and the Gut Microbiota in Adolescent and Adult Male Rats: A Vicious Cycle
Kawahara et al. Ghrelin restores D1 receptor-mediated dopamine neurotransmission and enhances attentive behaviour in Mecp2 KO mice
Scott Serotonin 1B Receptor Modulation of Cocaine Abuse-Like Behavior in Female Rats Before and After Abstinence From Self-Administration
JP2017507941A (ja) 機械的な神経損傷を処置するための新規組成物
GB2561333A (en) Treatment of alcohol use disorder
Shaw Inherent individual differences in presynaptic dopamine dynamics govern cocaine-associated behavior
Steiner et al. Animal Models of Nicotine Addiction: Implications for Medications Development
WHITEHAIR et al. 137. RECENT DEVELOPMENTS IN PRIMATE GENOMICS: A SYMPOSIUM IN HONOR OF
GB2558788A (en) New therapeutic uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Herzliya

Applicant after: Prenia Neurotherapy Co.,Ltd.

Address before: Herzliya

Applicant before: Prenia Medical Development Co.,Ltd.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190705